NASDAQ:ADMA - ADMA Biologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.29 +0.01 (+0.19 %)
(As of 05/28/2018 06:00 AM ET)
Previous Close$5.29
Today's Range$5.25 - $5.34
52-Week Range$2.01 - $5.70
Volume35,714 shs
Average Volume166,536 shs
Market Capitalization$239.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics logoADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Debt-to-Equity Ratio1.76
Current Ratio4.92
Quick Ratio3.60

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.76 million
Price / Sales10.53
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book5.94

Profitability

EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-101.93%
Return on Equity-88.31%
Return on Assets-25.76%

Miscellaneous

Employees295
Outstanding Shares45,320,000

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics (NASDAQ:ADMA) released its earnings results on Monday, March, 5th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.27. The biotechnology company earned $12 million during the quarter, compared to analyst estimates of $6.68 million. ADMA Biologics had a negative net margin of 101.93% and a negative return on equity of 88.31%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for ADMA Biologics.

What price target have analysts set for ADMA?

2 equities research analysts have issued 1 year target prices for ADMA Biologics' shares. Their forecasts range from $5.00 to $10.00. On average, they expect ADMA Biologics' stock price to reach $7.50 in the next year. View Analyst Ratings for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
  • Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
  • Mr. Brian Lenz, VP & CFO (Age 46)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

Has ADMA Biologics been receiving favorable news coverage?

News headlines about ADMA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ADMA Biologics earned a coverage optimism score of 0.07 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.60%), BlackRock Inc. (0.09%), JPMorgan Chase & Co. (0.09%), Element Capital Management LLC (0.06%) and Spark Investment Management LLC (0.05%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman and James Mond. View Institutional Ownership Trends for ADMA Biologics.

Which major investors are buying ADMA Biologics stock?

ADMA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Element Capital Management LLC, Spark Investment Management LLC and BlackRock Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman and James Mond. View Insider Buying and Selling for ADMA Biologics.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $5.29.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $239.73 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (ADMA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ADMA Biologics (NASDAQ:ADMA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for ADMA Biologics in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 41.78%. The high price target for ADMA is $10.00 and the low price target for ADMA is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$6.50$9.00
Price Target Upside: 41.78% upside53.69% upside135.51% upside262.90% upside

ADMA Biologics (NASDAQ:ADMA) Consensus Price Target History

Price Target History for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018Maxim GroupSet Price TargetBuy$10.00MediumView Rating Details
11/14/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$5.00N/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

ADMA Biologics (NASDAQ:ADMA) Earnings History and Estimates Chart

Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS

ADMA Biologics (NASDAQ ADMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2018        
3/5/2018Q4 2017($0.51)($0.24)$6.68 million$12.00 millionViewN/AView Earnings Details
11/3/2017Q3 2017($0.51)$0.59$6.86 million$4.73 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.26)($0.55)$3.52 million$3.40 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.2830)($0.51)$3.35 million$2.63 millionViewN/AView Earnings Details
2/24/2017Q4 2016($0.33)($0.35)$2.80 million$3.33 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.42)($0.34)$2.32 million$2.94 millionViewN/AView Earnings Details
8/12/2016Q2($0.39)($0.50)$2.35 million$2.27 millionViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)$2.48 million$2.12 millionViewN/AView Earnings Details
3/23/2016Q4 2015($0.47)($0.44)$2.03 million$2.51 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.32)($0.37)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.32)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.38)($0.38)$1.52 million$1.41 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.37)($0.36)$1.37 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.43)$1.50 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ADMA Biologics (NASDAQ:ADMA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ADMA Biologics (NASDAQ ADMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.90%
Institutional Ownership Percentage: 37.42%
Insider Trading History for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ ADMA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2017Adam S GrossmanInsiderBuy485,000$2.15$1,042,750.00View SEC Filing  
11/9/2017Brian LenzCFOBuy6,500$2.15$13,975.0015,000View SEC Filing  
11/9/2017Eric I RichmanDirectorBuy25,000$2.15$53,750.0031,300View SEC Filing  
11/9/2017James MondCMOBuy10,000$2.15$21,500.0013,389View SEC Filing  
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.008,500View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.003,389View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00637,268View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.0056,558View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50636,768View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.006,000View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.0056,058View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81628,418View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ADMA Biologics (NASDAQ ADMA) News Headlines

Source:
DateHeadline
ADMA Bio files for $100M mixed shelf offering and stock sale by investorADMA Bio files for $100M mixed shelf offering and stock sale by investor
seekingalpha.com - May 20 at 9:11 AM
BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 MlnBRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln
www.reuters.com - May 19 at 8:54 AM
Who Owns Most Of ADMA Biologics Inc (NASDAQ:ADMA)?Who Owns Most Of ADMA Biologics Inc (NASDAQ:ADMA)?
finance.yahoo.com - May 18 at 5:03 PM
Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory InfectionsBlog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections
finance.yahoo.com - May 18 at 9:39 AM
BRIEF-Adma Biologics Granted U.S. Patent For Treating Respiratory InfectionsBRIEF-Adma Biologics Granted U.S. Patent For Treating Respiratory Infections
www.reuters.com - May 16 at 9:15 AM
ADMA Biologics Granted U.S. Patent for Treating Respiratory InfectionsADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
finance.yahoo.com - May 16 at 9:15 AM
ADMA Biologics (ADMA) Raised to "Hold" at ValuEngineADMA Biologics (ADMA) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 15 at 1:15 PM
BRIEF-ADMA Biologics Q1 Loss Per Share $0.39BRIEF-ADMA Biologics Q1 Loss Per Share $0.39
www.reuters.com - May 15 at 9:29 AM
ADMA Biologics misses by $0.08, misses on revenueADMA Biologics misses by $0.08, misses on revenue
seekingalpha.com - May 15 at 9:29 AM
Adma Biologics: 1Q Earnings SnapshotAdma Biologics: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 9:29 AM
Maxim Group Analysts Give ADMA Biologics (ADMA) a $10.00 Price TargetMaxim Group Analysts Give ADMA Biologics (ADMA) a $10.00 Price Target
www.americanbankingnews.com - May 14 at 6:28 PM
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to BiotestADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest
finance.yahoo.com - May 14 at 4:49 PM
Will ADMA Biologics Inc’s (NASDAQ:ADMA) Earnings Grow In The Next Couple Of Years?Will ADMA Biologics Inc’s (NASDAQ:ADMA) Earnings Grow In The Next Couple Of Years?
finance.yahoo.com - May 8 at 4:52 PM
ADMA Biologics (ADMA) Scheduled to Post Quarterly Earnings on ThursdayADMA Biologics (ADMA) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 1:28 AM
ADMA Biologics (ADMA) PT Set at $10.00 by Maxim GroupADMA Biologics (ADMA) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - April 24 at 1:22 PM
BRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its OwnershipBRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership
www.reuters.com - April 24 at 8:59 AM
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its OwnershipADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership
finance.yahoo.com - April 24 at 8:59 AM
ADMA Biologics (ADMA) Lifted to "Sell" at ValuEngineADMA Biologics (ADMA) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - April 7 at 10:27 AM
 Analysts Set $7.63 Target Price for ADMA Biologics (ADMA) Analysts Set $7.63 Target Price for ADMA Biologics (ADMA)
www.americanbankingnews.com - April 1 at 1:36 AM
ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - March 20 at 9:16 AM
When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?
finance.yahoo.com - March 12 at 5:53 PM
ADMA Biologics Reports Full Year 2017 Financial Results - GlobeNewswire (press release)ADMA Biologics Reports Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 7 at 9:12 AM
ADMA Biologics (ADMA) PT Set at $8.00 by Maxim GroupADMA Biologics (ADMA) PT Set at $8.00 by Maxim Group
www.americanbankingnews.com - March 5 at 7:20 PM
ADMA Biologics Reports Full Year 2017 Financial ResultsADMA Biologics Reports Full Year 2017 Financial Results
finance.yahoo.com - March 5 at 9:08 AM
1,102,200 Shares in ADMA Biologics Inc (ADMA) Purchased by Broadfin Capital LLC1,102,200 Shares in ADMA Biologics Inc (ADMA) Purchased by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:55 AM
Zacks: Analysts Expect ADMA Biologics Inc (ADMA) Will Post Quarterly Sales of $6.68 MillionZacks: Analysts Expect ADMA Biologics Inc (ADMA) Will Post Quarterly Sales of $6.68 Million
www.americanbankingnews.com - February 28 at 5:02 AM
ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors ConferenceADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
finance.yahoo.com - February 27 at 9:04 AM
A Day Traders Guide To Market PsychologyA Day Trader's Guide To Market Psychology
www.msn.com - February 16 at 8:51 AM
ADMA Biologics (ADMA) to Release Earnings on ThursdayADMA Biologics (ADMA) to Release Earnings on Thursday
www.americanbankingnews.com - February 15 at 1:44 AM
 Analysts Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $6.68 Million Analysts Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $6.68 Million
www.americanbankingnews.com - February 12 at 9:04 AM
 Analysts Expect ADMA Biologics Inc (ADMA) Will Announce Earnings of -$0.51 Per Share Analysts Expect ADMA Biologics Inc (ADMA) Will Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - February 10 at 1:14 AM
Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?
finance.yahoo.com - January 30 at 9:57 AM
ADMA Biologics Inc (ADMA) Expected to Announce Quarterly Sales of $6.68 MillionADMA Biologics Inc (ADMA) Expected to Announce Quarterly Sales of $6.68 Million
www.americanbankingnews.com - January 26 at 7:06 AM
 Brokerages Anticipate ADMA Biologics Inc (ADMA) to Post -$0.51 Earnings Per Share Brokerages Anticipate ADMA Biologics Inc (ADMA) to Post -$0.51 Earnings Per Share
www.americanbankingnews.com - January 24 at 1:20 AM
Brokerages Expect ADMA Biologics Inc (ADMA) to Announce ($0.51) EPSBrokerages Expect ADMA Biologics Inc (ADMA) to Announce ($0.51) EPS
www.americanbankingnews.com - January 13 at 5:06 PM
$6.68 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter$6.68 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - January 8 at 4:36 AM
ADMA Biologics (ADMA) versus Its Competitors Head-To-Head ContrastADMA Biologics (ADMA) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - December 29 at 8:08 AM
Zacks: Analysts Anticipate ADMA Biologics Inc (ADMA) Will Announce Earnings of -$0.51 Per ShareZacks: Analysts Anticipate ADMA Biologics Inc (ADMA) Will Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - December 21 at 3:28 PM
Analysts Anticipate ADMA Biologics Inc (ADMA) to Announce ($0.51) EPSAnalysts Anticipate ADMA Biologics Inc (ADMA) to Announce ($0.51) EPS
www.americanbankingnews.com - December 21 at 7:48 AM
Head to Head Contrast: ADMA Biologics (ADMA) & The CompetitionHead to Head Contrast: ADMA Biologics (ADMA) & The Competition
www.americanbankingnews.com - December 21 at 3:26 AM
Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?
finance.yahoo.com - December 15 at 11:49 AM
ADMA Biologics (ADMA) Files BLA For Its Third Plasma Collection Center - StreetInsider.comADMA Biologics (ADMA) Files BLA For Its Third Plasma Collection Center - StreetInsider.com
www.streetinsider.com - December 11 at 3:42 PM
ADMA Biologics (ADMA) Given a $8.00 Price Target by Maxim Group AnalystsADMA Biologics (ADMA) Given a $8.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - December 11 at 3:40 PM
ADMA Files Biologics License Application For Its Third Plasma Collection CenterADMA Files Biologics License Application For Its Third Plasma Collection Center
finance.yahoo.com - December 11 at 11:58 AM
Comparing ADMA Biologics (ADMA) and Its PeersComparing ADMA Biologics (ADMA) and Its Peers
www.americanbankingnews.com - December 8 at 11:30 PM
ADMA Biologics Inc (ADMA) Expected to Post Quarterly Sales of $6.68 MillionADMA Biologics Inc (ADMA) Expected to Post Quarterly Sales of $6.68 Million
www.americanbankingnews.com - December 5 at 3:54 AM
Head-To-Head Comparison: ADMA Biologics (ADMA) versus Its PeersHead-To-Head Comparison: ADMA Biologics (ADMA) versus Its Peers
www.americanbankingnews.com - December 1 at 9:32 PM
ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 11:20 AM
ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?
finance.yahoo.com - November 27 at 3:23 PM
Financial Comparison: ADMA Biologics (ADMA) versus Gilead Sciences (GILD)Financial Comparison: ADMA Biologics (ADMA) versus Gilead Sciences (GILD)
www.americanbankingnews.com - November 21 at 1:52 PM

SEC Filings

ADMA Biologics (NASDAQ:ADMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ADMA Biologics (NASDAQ:ADMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ADMA Biologics (NASDAQ ADMA) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.